Literature DB >> 15264240

Mutational analysis of PINX1 in hereditary prostate cancer.

Gregory A Hawkins1, Bao-Li Chang, S Lilly Zheng, Sarah D Isaacs, Kathleen E Wiley, Eugene R Bleecker, Patrick C Walsh, Deborah A Meyers, Jianfeng Xu, William B Isaacs.   

Abstract

BACKGROUND: Telomerase activity is increased in most tumors. PinX1 has recently been identified as a critical component in regulating telomerase activity. The PinX1 gene is located within chromosomal region 8p22-23, a region associated with LOH and potentially linked to increased prostate cancer risk.
METHODS: PINX1 was re-sequenced in 159 hereditary prostate cancer (HPC) probands. Four non-synonymous coding variants were genotyped in 159 HPC families.
RESULTS: Thirty-nine polymorphisms were identified in the HPC screening panel. Ten coding polymorphisms were identified, seven (Gln50His, Leu91Met, Gln206His, Arg215Ile, Thr220Ala, Ser254Cys, and Glu414Ala) of which were non-synonymous. The most common variants Thr220Ala and Ser254Cys were not significantly over-transmitted from affected parent to affected offspring.
CONCLUSIONS: Based on these results, we conclude that PINX1 is not a major factor for HPC risk.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15264240     DOI: 10.1002/pros.20075

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  10 in total

1.  The telomerase inhibitor PinX1 is a major haploinsufficient tumor suppressor essential for chromosome stability in mice.

Authors:  Xiao Zhen Zhou; Pengyu Huang; Rong Shi; Tae Ho Lee; Gina Lu; Zhihong Zhang; Roderick Bronson; Kun Ping Lu
Journal:  J Clin Invest       Date:  2011-03-23       Impact factor: 14.808

2.  Biological significance of PinX1 telomerase inhibitor in esophageal carcinoma treatment.

Authors:  Xiang-Kui Fan; Rui-Hua Yan; Xiang-Qun Geng; Jing-Shan Li; Xiang-Ming Chen; Jian-Zhe Li
Journal:  Exp Ther Med       Date:  2016-08-01       Impact factor: 2.447

3.  The correlation of genetic instability of PINX1 gene to clinico-pathological features of gastric cancer in the Chinese population.

Authors:  Yingyu Ma; Liang Wu; Cuiping Liu; Liqian Xu; Dongmei Li; Ji-Cheng Li
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-11       Impact factor: 4.553

4.  PinX1 regulation of telomerase activity and apoptosis in nasopharyngeal carcinoma cells.

Authors:  Xiao-Fen Lai; Cong-Xiang Shen; Zhong Wen; Yu-Hong Qian; Chao-Sheng Yu; Jun-Qi Wang; Ping-Neng Zhong; Hai-Li Wang
Journal:  J Exp Clin Cancer Res       Date:  2012-02-08

5.  PinX1: a sought-after major tumor suppressor at human chromosome 8p23.

Authors:  Xiao Zhen Zhou
Journal:  Oncotarget       Date:  2011-10

6.  PinX1 Is a Potential Prognostic Factor for Non-Small-Cell Lung Cancer and Inhibits Cell Proliferation and Migration.

Authors:  Shengguang Wang; Hua Zhang; Jianquan Zhu; Chenguang Li; Jinfang Zhu; Bowen Shi; Bin Zhang; Changli Wang
Journal:  Biomed Res Int       Date:  2017-07-26       Impact factor: 3.411

Review 7.  PinX1: structure, regulation and its functions in cancer.

Authors:  Hai-Long Li; Jun Song; Hong-Mei Yong; Ping-Fu Hou; Yan-Su Chen; Wen-Bo Song; Jin Bai; Jun-Nian Zheng
Journal:  Oncotarget       Date:  2016-10-04

8.  The depletion of PinX1 involved in the tumorigenesis of non-small cell lung cancer promotes cell proliferation via p15/cyclin D1 pathway.

Authors:  Xiao-Peng Tian; Xiao-Han Jin; Mei Li; Wei-Juan Huang; Dan Xie; Jia-Xing Zhang
Journal:  Mol Cancer       Date:  2017-04-04       Impact factor: 27.401

9.  PinX1-siRNA/mPEG-PEI-SPION combined with doxorubicin enhances the inhibition of glioma growth.

Authors:  Ling Long; Weiwei Wang; Xia-Dong Cai; DU Cheng; Xintao Shuai; Ying Peng
Journal:  Exp Ther Med       Date:  2014-02-26       Impact factor: 2.447

10.  PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway.

Authors:  Jian-Ye Liu; Dong Qian; Li-Ru He; Yong-Hong Li; Yi-Ji Liao; Shi-Juan Mai; Xiao-Peng Tian; Yan-Hui Liu; Jia-Xing Zhang; Hsiang-Fu Kung; Yi-Xin Zeng; Fang-Jian Zhou; Dan Xie
Journal:  Mol Cancer       Date:  2013-11-23       Impact factor: 27.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.